GlobeNewswire·Nov 20, 2025, 4:01 PM ET

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Olema Pharmaceuticals, Inc. closed an underwritten public offering of 11,500,000 common shares, including the full exercise of the underwriters' option for 1,500,000 additional shares.
The shares were sold at a public price of $19.00 per share.
Gross proceeds from the offering were approximately $218.5 million before deducting underwriting discounts, commissions, and estimated offering expenses.
TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital, Oppenheimer & Co., and H.C. Wainwright & Co. served as book-running managers for the transaction.
The offering was executed under a shelf registration statement on Form S-3 filed on January 6, 2025, and declared effective on January 15, 2025, alongside a Form S-3MEF filed on November 18, 2025.
Olema is advancing palazestrant (OP-1250), a complete estrogen receptor antagonist, in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor, in a Phase 1 study.